Skip to main content
NOVTNovanta Inc.Hold5.2·$159.46-0.67%
Open full analysis

Novanta Inc. (NOVT) Stock Analysis

Range Bound setup

HoldModerate Confidence

Technology · Scientific & Technical Instruments

Hold if already holding. Not a fresh buy at $159.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum.

Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across two segments: Automation Enabling Technologies ($500.8M revenue, laser beam steering, motion control, robotics) and Medical Solutions ($479.8M revenue,... Read more

$159.46+5.6% A.UpsideScore 5.2/10#10 of 14 Scientific & Technical Instruments
QualityF-score9 / 9FCF yield1.53%
Stop $148.27Target $168.41(resistance)A.R:R -0.6:1
Analyst target$175.00+9.7%2 analysts
$168.41our TP
$159.46price
$175.00mean
$180

Hold if already holding. Not a fresh buy at $159.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.2/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-15
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Aug 4, 202650d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Earnings estimates trending UP
Strong growth profile
Risks
Analyst target reached - limited upside remaining
Negative momentum
Elevated risk factors

Key Metrics

P/E (TTM)114.7
P/E (Fwd)38.7
Mkt Cap$5.7B
EV/EBITDA31.4
Profit Mgn5.3%
ROE5.2%
Rev Growth10.4%
Beta1.68
DividendNone
Rating analysts9

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C0.24bullish
IV84%elevated
Max Pain$80-49.8% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomertop-2 OEM medical customers
    10-K Item 1: 'two OEM customers, each operating primarily in the medical end market across multiple product lines, represented approximately 12% and 11%, respectively, of our consolidated revenue.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.1
Value Rank
2.9
Growth Rank
4.3

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.9
Obv
1.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.7<4.5A.R:R -0.6=NEGATIVEInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 50d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
46 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $144.13Resistance $171.85

Price Targets

$148
$168
A.Upside+5.6%
A.R:R-0.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-6.7% upside)
! NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING
! momentum at 2.7 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-04 (50d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NOVT stock a buy right now?

Hold if already holding. Not a fresh buy at $159.46, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $168.41 (+5.6%), stop $148.27 (−7.5%), A.R:R -0.6:1. Score 5.2/10, moderate confidence.

What is the NOVT stock price target?

Take-profit target: $168.41 (+5.6% upside). Target $168.41 (+5.6%), stop $148.27 (−7.5%), A.R:R -0.6:1. Stop-loss: $148.27.

What are the risks of investing in NOVT?

Analyst target reached - limited upside remaining; Negative momentum; Elevated risk factors.

Is NOVT overvalued or undervalued?

Novanta Inc. trades at a P/E of 114.7 (forward 38.7). TrendMatrix value score: 4.7/10. Verdict: Hold.

What do analysts say about NOVT?

9 analysts cover NOVT with a consensus score of 4.3/5. Average price target: $175.

What does Novanta Inc. do?Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across...

Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across two segments: Automation Enabling Technologies ($500.8M revenue, laser beam steering, motion control, robotics) and Medical Solutions ($479.8M revenue, insufflators, imaging, RFID, light engines). Revenue is earned from approximately 3,000 employees in 15+ countries selling proprietary components embedded in OEM customers' long-lifecycle systems. In 2025, two OEM medical customers represented approximately 12% and 11% of consolidated revenue, respectively.

Related stocks: CGNX (Cognex Corporation) · GRMN (Garmin Ltd.) · VNT (Vontier Corporation) · TRMB (Trimble Inc.) · MKSI (MKS Inc.)
Home Stocks NOVT

Latest news

Latest News

TipRanks54d ago
MarketBeat55d ago
Stock Titan55d ago
Stock Titan39d ago
My Everett News39d agoRestructuring
StockStory37d agoEarnings
MarketBeat59d agoAnalyst
Yahoo Finance56d ago
Newser.com39d agoEarnings
Benzinga6d ago
Benzinga7d agoMerger Acquisition
Benzinga33d ago
Benzinga34d agoEarnings
Benzinga35d agoEarnings
Benzinga35d agoEarnings
Benzinga35d ago
Benzinga35d agoEarnings